Information Provided By:
Fly News Breaks for October 2, 2015
NVDQ
Oct 2, 2015 | 07:51 EDT
Canaccord analyst Jason Mills said he views Novadaq Technologies' co-marketing agreement with Arthrex as another important building block for a management team that has already made a number of moves that have "significantly augmented" the company's ability to grow. The analyst, who thinks Novadaq will deliver "solid" Q3 results, would buy the recent dip in the stock amid the broader weakness in small-cap med-tech stocks. The firm keeps a Buy rating and $15.50 price target on Navadaq.
News For NVDQ From the Last 2 Days
There are no results for your query NVDQ